George Salem, MD
Gastroenterology · Oklahoma City, OKNPI 1659711356
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $930,276 of the $1,158,578 with a category attached, or 80.3%. 17 manufacturers reported payments, led by AbbVie at 32.0% of the total. Among gastroenterology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $1104.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$371K
- E.r. Squibb & Sons, L.L.C.$289K
- Lilly USA, LLC$215K
- Johnson & Johnson$179K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- Celltrion USA Inc.$18K
- plus $18K from 11 others
Across 1 payment — averaging $1300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$1K
What the payments were for
- Consulting fees$43,2284%
- Speaking & faculty fees$930,27680%
- Travel & lodging$169,12415%
- Food & beverage$15,8791%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 331 | $370,875 |
| E.r. Squibb & Sons, L.L.C. | 253 | $288,734 |
| Lilly USA, LLC | 219 | $215,058 |
| Johnson & Johnson | 142 | $178,877 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $69,503 |
| Celltrion USA Inc. | 17 | $17,757 |
| Pfizer | 10 | $14,832 |
| Bristol Myers Squibb | 22 | $2,462 |
| Medtronic | 1 | $155 |
| ERBE USA Inc | 1 | $85 |
| Braintree Laboratories, Inc. | 1 | $72 |
| Sanofi | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,158,578 in reported general payments places this provider in the 95th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 61 | $1,685,376 |
| Humira(Cf) PenAdalimumab | 52 | $546,412 |
| Skyrizi On-BodyRisankizumab-Rzaa | 17 | $333,931 |
| RinvoqUpadacitinib | 36 | $249,252 |
| EntyvioVedolizumab | 21 | $198,357 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 143 | $23,343 |
| Mesalamine | 40 | $13,593 |
| Colestipol Hcl | 43 | $3,813 |
| Dicyclomine Hcl | 75 | $1,596 |
| Omeprazole | 47 | $1,108 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 27 | $990 |
| LoperamideLoperamide Hcl | 42 | $937 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 39 | $707 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $512 |
| Ondansetron Hcl | 185 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $178,877 | $1,685,37661 claims |
| AbbVieRinvoq | $370,875 | $249,25236 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $69,503 | $198,35721 claims |
| Braintree Laboratories, Inc.Sutab | $72 | $23,343143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Oklahoma City
- Tauseef AliOklahoma City$536K
- Pooja SinghalOklahoma City$140K
- Hussein BitarOklahoma City$120K
- Trushar PatelOklahoma City$49K
- Matthew McBrideOklahoma City$33K
- Sanjay SikkaOklahoma City$31K
- Tony TranOklahoma City$11K
- Ahmad Al-TaeeOklahoma City$11K
- Sumit WaliaOklahoma City$10K
- Kenneth SeresOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.